These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 22605458)
1. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Ginestier C; Monville F; Wicinski J; Cabaud O; Cervera N; Josselin E; Finetti P; Guille A; Larderet G; Viens P; Sebti S; Bertucci F; Birnbaum D; Charafe-Jauffret E Stem Cells; 2012 Jul; 30(7):1327-37. PubMed ID: 22605458 [TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629 [TBL] [Abstract][Full Text] [Related]
3. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer. Walsh CA; Akrap N; Garre E; Magnusson Y; Harrison H; Andersson D; Jonasson E; Rafnsdottir S; Choudhry H; Buffa F; Ragoussis J; Ståhlberg A; Harris A; Landberg G PLoS One; 2020; 15(7):e0236187. PubMed ID: 32692762 [TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer. Choi AR; Park JR; Kim RJ; Kim SR; Cho SD; Jung JY; Nam JS Biochem Biophys Res Commun; 2012 Aug; 425(2):436-42. PubMed ID: 22846569 [TBL] [Abstract][Full Text] [Related]
6. Insights into the cell of origin in breast cancer and breast cancer stem cells. Lindeman GJ; Visvader JE Asia Pac J Clin Oncol; 2010 Jun; 6(2):89-97. PubMed ID: 20565420 [TBL] [Abstract][Full Text] [Related]
7. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207 [TBL] [Abstract][Full Text] [Related]
8. The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Cai C; Zhu X Mol Med Rep; 2012 May; 5(5):1191-6. PubMed ID: 22367735 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842 [TBL] [Abstract][Full Text] [Related]
10. Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Gopalan A; Yu W; Sanders BG; Kline K Cancer Lett; 2013 Jan; 328(2):285-96. PubMed ID: 23063651 [TBL] [Abstract][Full Text] [Related]
11. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Ma Y; Hao X; Zhang S; Zhang J Breast Cancer Res Treat; 2012 Jun; 133(2):473-85. PubMed ID: 21947651 [TBL] [Abstract][Full Text] [Related]
12. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Charafe-Jauffret E; Ginestier C; Bertucci F; Cabaud O; Wicinski J; Finetti P; Josselin E; Adelaide J; Nguyen TT; Monville F; Jacquemier J; Thomassin-Piana J; Pinna G; Jalaguier A; Lambaudie E; Houvenaeghel G; Xerri L; Harel-Bellan A; Chaffanet M; Viens P; Birnbaum D Cancer Res; 2013 Dec; 73(24):7290-300. PubMed ID: 24142344 [TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192 [TBL] [Abstract][Full Text] [Related]
14. Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation. Glinka Y; Mohammed N; Subramaniam V; Jothy S; Prud'homme GJ Biochem Biophys Res Commun; 2012 Sep; 425(4):775-80. PubMed ID: 22885184 [TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157 [TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590 [TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
18. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715 [TBL] [Abstract][Full Text] [Related]
19. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373 [TBL] [Abstract][Full Text] [Related]
20. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]